ESTRO 2025 - Abstract Book

S774

Clinical - Gynaecology

ESTRO 2025

Purpose/Objective: There is a pressing need for updated estimates of cervical cancer (CC) in the United States (US). We aim to provide the latest epidemiological estimates of CC in the US. Material/Methods: This study is a large-scale population cohort analysis aimed at elucidating the epidemiological trends of CC from January 2000 to December 2021. The analysis was conducted between June 2024 and July 2024, utilizing data from 17 cancer registries within the Surveillance, Epidemiology, and End Results (SEER) database. The cohort comprised 65,090 CC patients.

Results: From 2000 to 2021, the overall incidence of CC per 100,000 population declined from 9.7 to 7.4. For individuals younger than 34 years, the incidence decreased from 6.7 to 4.5, and for those aged 65 and above, it dropped from 14.0 to 9.2. The incidence for stage I has a significant reduction from 2.2 to 1.5, and stage IB decreased from 2.2 to 2.1. Conversely, the incidence of stage IV increased from 0.9 to 1.1. Surgical treatment predominates for stage IA patients, with trends remaining stable. In contrast, the proportion of stage IB patients undergoing surgical treatment decreased from 83.7% to 73.2%. For patients in stage II and above, radiotherapy has become increasingly prevalent, especially for stage II patients, with the rate of curative radiotherapy rising from below 59.2% to 68.7%. Notably, only 10% of patients aged 65 and above received surgical treatment.